Stock Price, News, Quote and Profile of LANTHEUS HOLDINGS INC(NASDAQ:LNTH) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

LANTHEUS HOLDINGS INC

NASDAQ:LNTH (4/19/2024, 4:20:00 PM)

After market: 63.81 0 (0%)

63.81

+1.48 (+2.37%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryHealth Care Equipment & Supplies

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap4.37B

PE10.24

Fwd PE9.51

Dividend YieldN/A

Analysts

IPO

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The company is headquartered in North Billerica, Massachusetts and currently employs 698 full-time employees. The company went IPO on 2015-06-25. The firm's products include precision diagnostics, radiopharmaceutical oncology, and strategic partnerships. Its precision diagnostic products assist healthcare professionals (HCPs) Find and Follow diseases, with a focus on cardiology. Its radiopharmaceutical oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Its strategic partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes the Company's license of RELISTOR to Bausch Health Companies, Inc. (Bausch). Its commercial products are used by oncologists, urologists, nuclear medicine physicians, cardiologists, sonographers, technologists, radiologists, and internal medicine physicians working in a variety of clinical settings.

Company Info

LANTHEUS HOLDINGS INC

331 Treble Cove Rd

North Billerica MASSACHUSETTS 01862

P: 19786718001

CEO: Mary Anne Heino

Employees: 698

Website: https://www.lantheus.com/

LNTH News

a day ago - Lantheus Holdings, Inc.Lantheus to Host First Quarter 2024 Earnings Conference Call and Webcast on May 2, 2024, at 8:00 a.m. Eastern Time

BEDFORD, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference...